Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to a tyrosine kinase inhibitor mediated by changes to the conformation space of the kinase.

Physical chemistry chemical physics : PCCP - 22 Feb 2023

Freire Thales Souza, Caracelli Ignez, Zukerman-Schpector Julio, Friedman Ran

Abstract excerpt

Gilteritinib is a highly selective and effective inhibitor of the FLT3/ITD mutated protein, and is used successfully in treating acute myeloid leukaemia (AML). Unfortunately, tumour cells gradually develop resistance to gilteritinib due to mutations in the molecular drug target. The atomistic details behind this observed resistance are not clear, since the protein structure of the complex is only available in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Tyrosine Kinase Inhibitors

Source

Identifiers

PMID: 36752538
DOI: 10.1039/d2cp05549j

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to a tyrosine kinase inhibitor mediated by changes to the conformation space of the kinase.PMID 36752538Read ↗

Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy.Semantic proximity Read ↗

The molecular mechanism behind resistance of the kinase FLT3 to the inhibitor quizartinib.Semantic proximity Read ↗

Deciphering the molecular mechanism of FLT3 resistance mutations.Semantic proximity Read ↗

Deciphering the mechanism of HM43239 inhibiting the mutant F691L resistant to gilteritinib in FMS-like tyrosine kinase 3.Semantic proximity Read ↗

Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR.Semantic proximity Read ↗

In silico evaluation of the resistance of the T790M variant of epidermal growth factor receptor kinase to cancer drug Erlotinib.Semantic proximity Read ↗

Revealing acquired resistance mechanisms of kinase-targeted drugs using an on-the-fly, function-site interaction fingerprint approachSemantic proximity Read ↗

Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational DynamicsSemantic proximity Read ↗

The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.Semantic proximity Read ↗

A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistanceSemantic proximity Read ↗

Investigation of molecular mechanism leading to gefitinib and osimertinib resistance against EGFR tyrosine kinase: molecular dynamics and binding free energy calculation.Semantic proximity Read ↗

Insight into drug resistance mechanisms and discovery of potential inhibitors against wild-type and L1196M mutant ALK from FDA-approved drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.